RxSight Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
On May 15, 2024, J. Andy Corley, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) for the sale of securities of our common stock. Mr. Corley’s Rule 10b5-1 Trading Plan, which has a term from August 19, 2024 to May 20, 2025, provides for the sale of up to 40,000 shares of common stock at a pre-determined limit price.
On May 21, 2024, Ron Kurtz M.D., Chief Executive Officer and President and a member of our Board of Directors, entered into a Rule 10b5-1 Trading Plan for the sale of securities of our common stock. Dr. Kurtz’s Rule 10b5-1 Trading Plan, which has a term from August 20, 2024 to August 15, 2025, provides for the sale of up to 180,000 shares of common stock pursuant to a series of market orders at pre-determined limit prices.
On June 3, 2024, Ilya Goldshleger, Ph.D., Co-President and Chief Operating Officer, entered into a Rule 10b5-1 Trading Plan for the sale of securities of our common stock. Dr. Goldshleger’s Rule 10b5-1 Trading Plan, which has a term from September 16, 2024 to September 15, 2025, provides for the exercise and saleof options for up to 295,529 shares of common stock pursuant to a series of market orders at pre-determined limit prices.
On June 7, 2024, Eric Weinberg., Co-President and Chief Commercial Officer, entered into a Rule 10b5-1 Trading Plan for the sale of securities of our common stock. Mr. Weinberg’s Rule 10b5-1 Trading Plan, which has a term from September 9, 2024 to September 9, 2025, provides for the sale of up to 100,000 shares of common stock pursuant to a series of market orders at pre-determined limit prices.
On March 12, 2024, Julie Andrews, amember of our Board of Directors, entered into a Rule 10b5-1 Trading Plan for the sale of securities of our common stock. Ms. Andrews’ Rule 10b5-1 Trading Plan, which has a term from June 14, 2024 to March 20, 2025, provides for the sale of up to 15,625 shares of common stock at a pre-determined limit price.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.